Will Pizii

Articles

Selinexor Demonstrates PFS Benefit in Advanced Endometrial Cancer, Including p53 Wild-Type Tumors

June 7th 2022

Selinexor generated a longer median progression-free survival compared with placebo in patients with advanced or recurrent endometrial cancer, including those with p53 wild-type tumors.

Adjuvant Pembrolizumab Demonstrates DFS Benefit in Key Subgroups of Resected Early-Stage NSCLC

June 7th 2022

Adjuvant pembrolizumab was found to generally improve disease-free survival over placebo in patients with completely resected early-stage non–small cell lung cancer, irrespective of type of surgical resection, tumor size, and type or extent of adjuvant chemotherapy.

Adjuvant Pembrolizumab Results in Significant DMFS Improvement Over Placebo in Stage II Melanoma

June 5th 2022

Adjuvant pembrolizumab was found to result in a significant improvement in distant metastasis-free survival compared with placebo, with a continued reduction in risk of recurrence and an acceptable safety profile, in patients with resected stage IIB or stage IIC melanoma.

ARAFOR Data Reveal Favorable Safety, Tolerability With Long-Term Darolutamide Exposure in mCRPC

May 14th 2022

Darolutamide was found to have a favorable safety and tolerability profile in patients with metastatic castration-resistant prostate cancer who were enrolled to the phase 1 ARAFOR study and received extended treatment with the agent for more than 4 years.

Ruxolitinib Could Prevent Serious GVHD Following Allogeneic HCT

April 25th 2022

The use of ruxolitinib following an allogeneic hematopoietic cell transplantation was associated with the prevention of serious graft-versus-host disease.

Nivolumab/Chemotherapy Generate Survival Benefit Vs Chemotherapy Alone in Gastric Cancer, Regardless of TMB

April 11th 2022

The combination of nivolumab with chemotherapy elicited a higher overall survival rate compared with chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, regardless of tumor mutational burden (TMB) status.

Cabozantinib Dose Reduction Improves Survival in Patients With mRCC

February 19th 2022

A reduction in cabozantinib dosage because of toxicity demonstrated improved time to treatment failure and overall survival in patients with metastatic renal cell carcinoma.

FDG and NaF PET/CT Imaging Prognostic for OS in Metastatic GU Cancers Treated With Cabozantinib/Nivolumab Combos

February 18th 2022

Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT baseline functional imaging parameters and percent change in lesion number observed on follow-up imaging was linked with overall survival and found to be prognostic in patients with metastatic genitourinary cancers.

Nivolumab Plus mFOLFOX6 and Bevacizumab Misses PFS End Point in mCRC

January 23rd 2022

The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.

Trastuzumab Deruxtecan Demonstrates Sustained Efficacy in HER2+ mCRC

January 22nd 2022

Trastuzumab deruxtecan demonstrated durable responses and a safety profile that was consistent with findings from the primary analysis of the phase 2 DESTINY-CRC01 trial in pretreated patients with HER2-expressing metastatic colorectal cancer, according to updated results of the study.

Frontline Axi-Cel Elicits Durable Responses in High-Risk LBCL

December 14th 2021

Frontline treatment with axicabtagene ciloleucel demonstrated rapid and durable responses in patients with high-risk large B-cell lymphoma.

Parsaclisib Elicits Lasting Responses in Relapsed/Refractory Marginal Zone Lymphoma

December 11th 2021

Parsaclisib demonstrated early and long-lasting responses in patients with BTK-naïve, relapsed/refractory marginal zone lymphoma, according to findings from the phase 2 CITADEL-204 trial.

Samuraciclib Plus Fulvestrant Improves PFS in Heavily Pretreated HR+ Breast Cancer

December 10th 2021

Fulvestrant plus the CDK7 inhibitor samuraciclib demonstrated encouraging efficacy in patients with hormone receptor-positive breast cancer who were heavily pretreated with CDK4/6 inhibitors.